Most indications (HER2-positive/low breast cancer, HER-2 positive cancers) have retained the 5.4 mg/kg schedule, excepting the treatment of HER2-positive gastric cancer (6.4 mg/kg), based on efficacy/tolerance issues but without formal comparison of the two doses [61]. This evidence concerns the gene ERBB2 and breast carcinoma.